{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:16:58Z","timestamp":1760401018235,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcte.2025.100407","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T12:07:48Z","timestamp":1751458068000},"page":"100407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-8027","authenticated-orcid":false,"given":"Esp\u00e9rie","family":"Burnet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Larger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Camus-Bablon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Mifsud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Fesenbeckh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Mosnier-Pudar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcte.2025.100407_b0005","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen et al.","author":"Olesen","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2025.100407_b0010","unstructured":"Registre fran\u00e7aise de la mucoviscidose - Bilan des donn\u00e9es 202Paris; 2023 Sep."},{"key":"10.1016\/j.jcte.2025.100407_b0015","unstructured":"AAAA 2022 Patient Registry Annual Data Report. Cystic Fibrosis Foundation Patient Registry; 2022."},{"key":"10.1016\/j.jcte.2025.100407_b0020","unstructured":"UK Cystic Fibrosis Registry - 2022 Annual Data Report [Internet]. 2022. Available from: https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2023-12\/CFT_2022_Annual_Data_Report_Dec2023.pdf."},{"issue":"2","key":"10.1016\/j.jcte.2025.100407_b0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcte.2025.100407_b0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcf.2004.08.001","article-title":"Clinical importance of cystic fibrosis-related diabetes","volume":"3","author":"Brennan","year":"2004","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"8","key":"10.1016\/j.jcte.2025.100407_b0035","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ppul.21495","article-title":"Cystic fibrosis related diabetes (CFRD)\u2014The end stage of progressive insulin deficiency","volume":"46","author":"Hameed","year":"2011","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcte.2025.100407_b0040","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis-related diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jcte.2025.100407_b0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jcf.2022.12.013","article-title":"Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis","volume":"22","author":"Dong","year":"2023","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"8","key":"10.1016\/j.jcte.2025.100407_b0050","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Larsen Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"10212","key":"10.1016\/j.jcte.2025.100407_b0055","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"19","key":"10.1016\/j.jcte.2025.100407_b0060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcte.2025.100407_b0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"17","key":"10.1016\/j.jcte.2025.100407_b0070","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcte.2025.100407_b0075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcte.2025.100407_b0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcte.2025.100407_b0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcte.2025.100407_b0090","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcte.2025.100407_b0095","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"10.1016\/j.jcte.2025.100407_b0100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcte.2025.100407_b0105","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"8","key":"10.1016\/j.jcte.2025.100407_b0110","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc08-1987","article-title":"New definition for the partial remission period in children and adolescents with type 1 diabetes","volume":"32","author":"Mortensen","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jcte.2025.100407_b0115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/pedi.12208","article-title":"Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes","volume":"15","author":"Max Andersen","year":"2014","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"10.1016\/j.jcte.2025.100407_b0120","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American diabetes association and a clinical practice guideline of the cystic fibrosis foundation, endorsed by the pediatric endocrine society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcte.2025.100407_b0125","article-title":"The French compassionate program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"16","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcte.2025.100407_b0130","unstructured":"Gallucci M. GAMLj3: GAMLj Suite for Linear Models. R package version 3.3.9 [Internet]. 2024 [cited 2024 Sep 2]. Available from: https:\/\/www.jamovi.org\/."},{"issue":"6","key":"10.1016\/j.jcte.2025.100407_b0135","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/pedi.12413","article-title":"Factors contributing to partial remission in type 1 diabetes: analysis based on the insulin dose-adjusted HbA1c in 3657 children and adolescents from Germany and Austria","volume":"18","author":"Nagl","year":"2017","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"10.1016\/j.jcte.2025.100407_b0140","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00125-015-3559-y","article-title":"CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes","volume":"58","author":"Buckingham","year":"2015","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.jcte.2025.100407_b0145","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00125-024-06124-5","article-title":"The INNODIA type 1 diabetes natural history study: a European cohort of newly diagnosed children, adolescents and adults","volume":"67","author":"Marcovecchio","year":"2024","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.jcte.2025.100407_b0150","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.jcte.2025.100407_b0155","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of elexacaftor-tezacaftor-ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcte.2025.100407_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcte.2025.100407_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"14","key":"10.1016\/j.jcte.2025.100407_b0170","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcte.2025.100407_b0175","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"11","key":"10.1016\/j.jcte.2025.100407_b0180","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor\u2013tezacaftor\u2013ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.jcte.2025.100407_b0185","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00125-024-06151-2","article-title":"Discordance between mean glucose and time in range in relation to HbA1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials","volume":"67","author":"Sterner Isaksson","year":"2024","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.jcte.2025.100407_b0190","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623725000250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623725000250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:20:44Z","timestamp":1760336444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214623725000250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"alternative-id":["S2214623725000250"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2025.100407","relation":{},"ISSN":["2214-6237"],"issn-type":[{"type":"print","value":"2214-6237"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2025.100407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100407"}}